Logo image of CRI

CARTER'S INC (CRI) Stock Fundamental Analysis

NYSE:CRI - New York Stock Exchange, Inc. - US1462291097 - Common Stock - Currency: USD

31.39  -0.97 (-3%)

After market: 31.66 +0.27 (+0.86%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to CRI. CRI was compared to 48 industry peers in the Textiles, Apparel & Luxury Goods industry. CRI has an excellent financial health rating, but there are some minor concerns on its profitability. CRI has a bad growth rate and is valued cheaply. CRI also has an excellent dividend rating. These ratings would make CRI suitable for value and dividend investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

In the past year CRI was profitable.
In the past year CRI had a positive cash flow from operations.
Each year in the past 5 years CRI has been profitable.
Each year in the past 5 years CRI had a positive operating cash flow.
CRI Yearly Net Income VS EBIT VS OCF VS FCFCRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

1.2 Ratios

Looking at the Return On Assets, with a value of 8.45%, CRI is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
Looking at the Return On Equity, with a value of 23.26%, CRI is in the better half of the industry, outperforming 79.17% of the companies in the same industry.
CRI's Return On Invested Capital of 12.72% is fine compared to the rest of the industry. CRI outperforms 75.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CRI is in line with the industry average of 13.45%.
Industry RankSector Rank
ROA 8.45%
ROE 23.26%
ROIC 12.72%
ROA(3y)9.05%
ROA(5y)8.18%
ROE(3y)26.4%
ROE(5y)25.22%
ROIC(3y)13.75%
ROIC(5y)13.22%
CRI Yearly ROA, ROE, ROICCRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

CRI has a Profit Margin of 5.67%. This is in the better half of the industry: CRI outperforms 62.50% of its industry peers.
CRI's Profit Margin has declined in the last couple of years.
CRI has a better Operating Margin (8.95%) than 60.42% of its industry peers.
In the last couple of years the Operating Margin of CRI has declined.
CRI's Gross Margin of 47.68% is in line compared to the rest of the industry. CRI outperforms 45.83% of its industry peers.
In the last couple of years the Gross Margin of CRI has grown nicely.
Industry RankSector Rank
OM 8.95%
PM (TTM) 5.67%
GM 47.68%
OM growth 3Y-11.06%
OM growth 5Y-2.63%
PM growth 3Y-12.75%
PM growth 5Y-2.95%
GM growth 3Y0.38%
GM growth 5Y2.29%
CRI Yearly Profit, Operating, Gross MarginsCRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

7

2. Health

2.1 Basic Checks

CRI has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, CRI has less shares outstanding
CRI has less shares outstanding than it did 5 years ago.
The debt/assets ratio for CRI has been reduced compared to a year ago.
CRI Yearly Shares OutstandingCRI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CRI Yearly Total Debt VS Total AssetsCRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 3.26 indicates that CRI is not in any danger for bankruptcy at the moment.
CRI has a Altman-Z score (3.26) which is in line with its industry peers.
CRI has a debt to FCF ratio of 2.25. This is a good value and a sign of high solvency as CRI would need 2.25 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 2.25, CRI is doing good in the industry, outperforming 72.92% of the companies in the same industry.
CRI has a Debt/Equity ratio of 0.59. This is a neutral value indicating CRI is somewhat dependend on debt financing.
CRI's Debt to Equity ratio of 0.59 is on the low side compared to the rest of the industry. CRI is outperformed by 62.50% of its industry peers.
Although CRI does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF 2.25
Altman-Z 3.26
ROIC/WACC1.27
WACC9.98%
CRI Yearly LT Debt VS Equity VS FCFCRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.3 Liquidity

CRI has a Current Ratio of 2.56. This indicates that CRI is financially healthy and has no problem in meeting its short term obligations.
CRI has a Current ratio of 2.56. This is in the better half of the industry: CRI outperforms 64.58% of its industry peers.
A Quick Ratio of 1.40 indicates that CRI should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.40, CRI is in the better half of the industry, outperforming 64.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.56
Quick Ratio 1.4
CRI Yearly Current Assets VS Current LiabilitesCRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

1

3. Growth

3.1 Past

CRI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.39%.
CRI shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.36% yearly.
Looking at the last year, CRI shows a decrease in Revenue. The Revenue has decreased by -3.69% in the last year.
Measured over the past years, CRI shows a decrease in Revenue. The Revenue has been decreasing by -4.17% on average per year.
EPS 1Y (TTM)-9.39%
EPS 3Y-8.37%
EPS 5Y-1.36%
EPS Q2Q%-36.54%
Revenue 1Y (TTM)-3.69%
Revenue growth 3Y-6.56%
Revenue growth 5Y-4.17%
Sales Q2Q%-4.79%

3.2 Future

Based on estimates for the next years, CRI will show a very negative growth in Earnings Per Share. The EPS will decrease by -24.84% on average per year.
The Revenue is expected to decrease by -0.86% on average over the next years.
EPS Next Y-45.09%
EPS Next 2Y-35.19%
EPS Next 3Y-24.84%
EPS Next 5YN/A
Revenue Next Year-1.61%
Revenue Next 2Y-1.27%
Revenue Next 3Y-0.86%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CRI Yearly Revenue VS EstimatesCRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B
CRI Yearly EPS VS EstimatesCRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 5.52 indicates a rather cheap valuation of CRI.
97.92% of the companies in the same industry are more expensive than CRI, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.82, CRI is valued rather cheaply.
A Price/Forward Earnings ratio of 12.31 indicates a correct valuation of CRI.
Based on the Price/Forward Earnings ratio, CRI is valued a bit cheaper than 70.83% of the companies in the same industry.
CRI's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.76.
Industry RankSector Rank
PE 5.52
Fwd PE 12.31
CRI Price Earnings VS Forward Price EarningsCRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CRI indicates a rather cheap valuation: CRI is cheaper than 95.83% of the companies listed in the same industry.
CRI's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CRI is cheaper than 89.58% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.17
EV/EBITDA 3.7
CRI Per share dataCRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80

4.3 Compensation for Growth

CRI has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as CRI's earnings are expected to decrease with -24.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.19%
EPS Next 3Y-24.84%

7

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 8.82%, CRI is a good candidate for dividend investing.
The stock price of CRI dropped by -39.69% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
Compared to an average industry Dividend Yield of 3.59, CRI pays a better dividend. On top of this CRI pays more dividend than 97.92% of the companies listed in the same industry.
CRI's Dividend Yield is rather good when compared to the S&P500 average which is at 2.36.
Industry RankSector Rank
Dividend Yield 8.82%

5.2 History

The dividend of CRI is nicely growing with an annual growth rate of 16.75%!
CRI has been paying a dividend for at least 10 years, so it has a reliable track record.
CRI has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)16.75%
Div Incr Years1
Div Non Decr Years4
CRI Yearly Dividends per shareCRI Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3

5.3 Sustainability

58.78% of the earnings are spent on dividend by CRI. This is a bit on the high side, but may be sustainable.
CRI's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP58.78%
EPS Next 2Y-35.19%
EPS Next 3Y-24.84%
CRI Yearly Income VS Free CF VS DividendCRI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M
CRI Dividend Payout.CRI Dividend Payout, showing the Payout Ratio.CRI Dividend Payout.PayoutRetained Earnings

CARTER'S INC

NYSE:CRI (5/23/2025, 9:24:29 PM)

After market: 31.66 +0.27 (+0.86%)

31.39

-0.97 (-3%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Durables & Apparel
GICS IndustryTextiles, Apparel & Luxury Goods
Earnings (Last)04-25 2025-04-25/bmo
Earnings (Next)07-24 2025-07-24/bmo
Inst Owners121.46%
Inst Owner Change-3.12%
Ins Owners1.59%
Ins Owner Change16.74%
Market Cap1.14B
Analysts47.14
Price Target29.58 (-5.77%)
Short Float %15.42%
Short Ratio3.06
Dividend
Industry RankSector Rank
Dividend Yield 8.82%
Yearly Dividend3.2
Dividend Growth(5Y)16.75%
DP58.78%
Div Incr Years1
Div Non Decr Years4
Ex-Date03-10 2025-03-10 (0.8)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.6%
Min EPS beat(2)23.39%
Max EPS beat(2)33.81%
EPS beat(4)4
Avg EPS beat(4)32.42%
Min EPS beat(4)19.02%
Max EPS beat(4)53.46%
EPS beat(8)8
Avg EPS beat(8)25.48%
EPS beat(12)10
Avg EPS beat(12)23.14%
EPS beat(16)14
Avg EPS beat(16)25.97%
Revenue beat(2)1
Avg Revenue beat(2)0.79%
Min Revenue beat(2)-0.04%
Max Revenue beat(2)1.63%
Revenue beat(4)1
Avg Revenue beat(4)-0.17%
Min Revenue beat(4)-1.64%
Max Revenue beat(4)1.63%
Revenue beat(8)2
Avg Revenue beat(8)-0.3%
Revenue beat(12)4
Avg Revenue beat(12)-0.3%
Revenue beat(16)7
Avg Revenue beat(16)-0.21%
PT rev (1m)-36.61%
PT rev (3m)-47.75%
EPS NQ rev (1m)2.04%
EPS NQ rev (3m)-42.04%
EPS NY rev (1m)-11.35%
EPS NY rev (3m)-33.14%
Revenue NQ rev (1m)0.93%
Revenue NQ rev (3m)0.88%
Revenue NY rev (1m)-1.06%
Revenue NY rev (3m)-1.16%
Valuation
Industry RankSector Rank
PE 5.52
Fwd PE 12.31
P/S 0.33
P/FCF 5.17
P/OCF 4.15
P/B 1.35
P/tB 3.28
EV/EBITDA 3.7
EPS(TTM)5.69
EY18.13%
EPS(NY)2.55
Fwd EY8.12%
FCF(TTM)6.07
FCFY19.34%
OCF(TTM)7.57
OCFY24.1%
SpS95.33
BVpS23.25
TBVpS9.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 8.45%
ROE 23.26%
ROCE 16.17%
ROIC 12.72%
ROICexc 15.26%
ROICexgc 22.16%
OM 8.95%
PM (TTM) 5.67%
GM 47.68%
FCFM 6.37%
ROA(3y)9.05%
ROA(5y)8.18%
ROE(3y)26.4%
ROE(5y)25.22%
ROIC(3y)13.75%
ROIC(5y)13.22%
ROICexc(3y)16.52%
ROICexc(5y)18.31%
ROICexgc(3y)24.79%
ROICexgc(5y)28.26%
ROCE(3y)17.48%
ROCE(5y)16.81%
ROICexcg growth 3Y-19.15%
ROICexcg growth 5Y0.36%
ROICexc growth 3Y-17.36%
ROICexc growth 5Y-0.7%
OM growth 3Y-11.06%
OM growth 5Y-2.63%
PM growth 3Y-12.75%
PM growth 5Y-2.95%
GM growth 3Y0.38%
GM growth 5Y2.29%
F-Score7
Asset Turnover1.49
Health
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF 2.25
Debt/EBITDA 1.36
Cap/Depr 96.71%
Cap/Sales 1.57%
Interest Coverage 250
Cash Conversion 75.08%
Profit Quality 112.24%
Current Ratio 2.56
Quick Ratio 1.4
Altman-Z 3.26
F-Score7
WACC9.98%
ROIC/WACC1.27
Cap/Depr(3y)84.08%
Cap/Depr(5y)65.4%
Cap/Sales(3y)1.75%
Cap/Sales(5y)1.49%
Profit Quality(3y)119.52%
Profit Quality(5y)187.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.39%
EPS 3Y-8.37%
EPS 5Y-1.36%
EPS Q2Q%-36.54%
EPS Next Y-45.09%
EPS Next 2Y-35.19%
EPS Next 3Y-24.84%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.69%
Revenue growth 3Y-6.56%
Revenue growth 5Y-4.17%
Sales Q2Q%-4.79%
Revenue Next Year-1.61%
Revenue Next 2Y-1.27%
Revenue Next 3Y-0.86%
Revenue Next 5YN/A
EBIT growth 1Y-17.87%
EBIT growth 3Y-16.9%
EBIT growth 5Y-6.69%
EBIT Next Year3.01%
EBIT Next 3Y-0.41%
EBIT Next 5YN/A
FCF growth 1Y-10.76%
FCF growth 3Y1.66%
FCF growth 5Y-5.73%
OCF growth 1Y-6.35%
OCF growth 3Y3.65%
OCF growth 5Y-5.05%